Foghorn Therapeutics Inc. (FHTX)

Market Cap	195.76M
Revenue (ttm)	22.60M
Net Income (ttm)	-86.62M
Shares Out	55.61M
EPS (ttm)	-1.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,527
Open	3.870
Previous Close	3.880
Day's Range	3.510 - 3.870
52-Week Range	3.515 - 10.250
Beta	3.13
Analysts	Strong Buy
Price Target	13.17 (+274.15%)
Earnings Date	Mar 6, 2025

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and l...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 23, 2020
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: FHTX
• Website: https://foghorntx.com

Financial Performance

In 2024, Foghorn Therapeutics's revenue was $22.60 million, a decrease of -33.83% compared to the previous year's $34.16 million. Losses were -$86.62 million, -11.99% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price forecast is $13.17, which is an increase of 274.15% from the latest price.

Price Target

$13.17

(274.15% upside)

Analyst Consensus: Strong Buy